Literature DB >> 19896837

HMGA1 protein expression in familial breast carcinoma patients.

Gennaro Chiappetta1, Alessandro Ottaiano, Emilia Vuttariello, Mario Monaco, Francesca Galdiero, Adolfo Gallipoli, Silvana Pilotti, Giovanna Jodice, Manoukian Siranoush, Mara Colombo, Carla B Ripamonti, Pier Lorenzo Pallante, Paolo Radice, Alfredo Fusco.   

Abstract

HMGA protein overexpression is associated with a highly malignant phenotype and it is also causally related to neoplastic cell transformation. Our previous results have shown that HMGA1 was not expressed in normal breast tissue whereas HMGA1 staining was intense in 25% of hyperplastic lesions with cellular atypia and in 60% of sporadic ductal carcinomas. Moreover, HMGA1 protein levels were significantly correlated with c-Erb-B2 expression. These results suggested HMGA1 expression as a novel prognostic factor in breast ductal carcinomas. In order to investigate whether the HMGA1 detection might have a prognostic role also for inherited breast carcinomas we have analysed the expression of the HMGA1 proteins in 116 breast familial carcinomas associated with BRCA1 or BRCA2 or negative for mutations in both genes (BRCAX). HMGA1 expression was weakly positive in 23 (20%), moderately positive in 34 (29%) and strongly positive in 20 (17%) breast carcinomas, and was not detected in 39 of them (34%). Statistical analysis of the immunostaining data showed that HMGA1 was significantly overexpressed, with a more intense staining, in BRCA2 (p=0.0009) and BRCAX (p=0.0134) patients compared to BRCA1 ones. Furthermore, in BRCA2 positive patients, the expression of HMGA1 seems to correlate with a favourable prognosis with a median overall survival of 65 months and a 5-year survival rate of 80% for HMGA1-negative patients, while median overall survival in the HMGA1-positive subsets was not reached with 5-year survival rates ranging from 84% to 100% of patients (p=0.0198). Conversely, no correlation was found between HMGA1 expression and overall survival in patients carrying inherited mutations in the BRCA1 and in BRCAX patients. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896837     DOI: 10.1016/j.ejca.2009.10.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Innovative Breast Cancer Biomarkers.

Authors:  Angelo Paradiso; Rosella Silvestrini; Gennaro Chiappetta
Journal:  Breast Care (Basel)       Date:  2010-04-13       Impact factor: 2.860

Review 2.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

3.  High-Mobility Group A (HMGA) Proteins and Breast Cancer.

Authors:  Silvia Peluso; Gennaro Chiappetta
Journal:  Breast Care (Basel)       Date:  2010-04-09       Impact factor: 2.860

4.  Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy.

Authors:  Ebru Güçlü; Canan Eroğlu Güneş; Ercan Kurar; Hasibe Vural
Journal:  Med Oncol       Date:  2021-08-11       Impact factor: 3.064

Review 5.  High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.

Authors:  Lu Wang; Ji Zhang; Min Xia; Chang Liu; Xuyu Zu; Jing Zhong
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

6.  HMGA1 interacts with β-catenin to positively regulate Wnt/β-catenin signaling in colorectal cancer cells.

Authors:  Junjie Xing; Guangwen Cao; Chuangang Fu
Journal:  Pathol Oncol Res       Date:  2014-04-03       Impact factor: 3.201

Review 7.  Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.

Authors:  Alexandra J van den Broek; Marjanka K Schmidt; Laura J van 't Veer; Rob A E M Tollenaar; Flora E van Leeuwen
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

8.  Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer.

Authors:  Elisa Maurizio; Jacek R Wiśniewski; Yari Ciani; Angela Amato; Laura Arnoldo; Carlotta Penzo; Silvia Pegoraro; Vincenzo Giancotti; Alberto Zambelli; Silvano Piazza; Guidalberto Manfioletti; Riccardo Sgarra
Journal:  Mol Cell Proteomics       Date:  2015-11-02       Impact factor: 5.911

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.